TrialESMO open2026

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

G Curigliano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.